Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33333673

about

Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Systemic treatment of hepatocellular carcinoma: Past, present and future Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis.Hepatocellular carcinoma: are we making progress?Targeted therapy in hepatocellular carcinoma Systemic therapies for hepatocellular carcinoma.Hepatocellular carcinoma: therapy and prevention.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.Treatment of hepatocellular carcinoma: a systematic review.Current management of hepatocellular carcinoma: an Eastern perspective.Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma.Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo.Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma?Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.A rare case report: carcinoma pancreas with hepatocellular carcinoma Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.Hepatobiliary transporter expression in human hepatocellular carcinoma.

P2860

Q24247259-2D6A4642-DCFC-47C2-9C51-174F964DC4AE Q27693179-E3E29FDF-EE20-430C-8FD3-69885BC72ED1 Q28392783-89E5504C-A653-4D36-88B8-57979DEF6B9B Q28394414-27768248-9588-4E78-A73B-AF7864412363 Q30479629-5943A480-CCA2-4EAE-8DEA-0D5065774670 Q33340185-896A1D3A-D048-4B35-88B8-484369DDEC6E Q33343204-3AE9DAE4-327B-4FA2-91EB-73A87E5C9D78 Q33349102-C5359520-3737-44DF-88FD-E70098D4683B Q33358104-FFA964C2-C0AB-4D45-827E-9739DB70703E Q33379418-AEBB496B-8B47-4FFB-B999-1518B13B9285 Q33395245-1D34BD00-CAF2-4BF4-8DA0-1395E6BD0D0A Q33402113-C875027E-4B37-48F5-A318-FF2A3F70B885 Q33635033-851264A5-E5B5-4B4B-9D2F-8CC695A8AC2A Q33854034-97E63D21-27D1-4BDA-9D2D-87225EE579F8 Q35180039-07AC15FA-7B8A-41A6-9F47-8E4D393A206F Q35193283-2BA5CA53-E121-4745-BD75-58BF85CF79D4 Q35207561-C6F4D30E-4C8C-4B65-8B78-A0D127271244 Q35964708-763C5FF3-1FEB-4B63-A47F-CDEA080631B6 Q36377949-39DE6977-89B0-4FBF-9B0A-FA5BC209AF85 Q36671639-F4A7AD22-E14C-4068-B5E3-0D1BD4121AB5 Q37322087-9FC7AF65-7D7A-4D71-BEEF-F2F85FA23126 Q37734197-111A8322-1083-4495-8CE2-C6D63B3D84B2 Q38081222-7067502C-672B-42AB-BB45-8E272E12240D Q38155508-A1ADA6EE-2408-4A34-9B9A-2E07A972E9BE Q38410816-12137F0F-54BD-451D-BD8E-7587D69F8690 Q39013493-1DF18645-7877-4D7D-A6AF-E977134A8135 Q39289689-B4A1258F-C655-4D04-8FF0-0F25E253BF73 Q39859377-E37AE535-6791-44F0-AF5A-2AB15DD860DF Q40002016-65D073F9-6B08-4208-9872-878820402893 Q40183947-717290F2-6642-43A4-9833-F250FE7B8D08 Q41808165-4D095883-3C54-4612-A2C7-CD6E32E9C23E Q41970476-D86C8181-7170-4C1C-848C-B675B54D9948 Q42343451-AF34FE0A-1644-4464-9889-02CF0D9779AF Q47869247-176608AE-24A1-4C86-AAA8-62C45C517F46 Q53025755-6CDC61EE-C91E-42AB-BB08-02446C4CE5D7 Q54674953-BC82852B-406B-4548-9DAB-83BF46E41962

P2860

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33333673

description

2000 nî lūn-bûn

@nan

2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@ast

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@en

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@nl

type

label

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@ast

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@en

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@nl

prefLabel

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@ast

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@en

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@nl

P1433

Q33333673-B9FD843A-BAC9-4EED-8221-FED38D3A975A

P1476

Q33333673-9A932A72-DDFA-45B5-A352-B49FCC6E4F54

P2093

Q33333673-44DFC1B6-244D-4954-93C6-D229AAE89101

Q33333673-58DA4E6F-8098-414B-B951-AAF39868661A

Q33333673-9BDC8EAA-6D60-4FFE-934D-ACF5D16E7339

Q33333673-AE8FEE68-01D1-43F9-B57C-9257908E5D45

Q33333673-F6579ACA-84C5-4974-92BA-66FE47184492

P2860

Q33333673-28E63548-DC41-4381-9918-85C1DD870A21

Q33333673-4733D92E-0093-4BA6-82E8-B741BE6061D0

Q33333673-6C8179EC-B5F9-42DA-905C-B339F905ECD8

Q33333673-71102626-9E73-4415-9CA5-C37E7D47F2C3

Q33333673-856C3F10-B521-4797-B502-25E6FAF6F628

Q33333673-89142185-4E7E-4013-A075-B0D930BB955A

Q33333673-92A6F1B5-0ECE-4BB8-A14A-8F2EB6DAC984

Q33333673-B6165B94-B1A2-490D-A18A-3D402D26BAF5

Q33333673-B96CBA2A-9D6C-4E99-ABAE-FD4045487526

Q33333673-C6F4AFF2-C052-459E-80FF-2116F69AEE26

P304

Q33333673-36C6AE1B-8A23-4956-BA00-170D5F606E27

P31

Q33333673-DC75F71C-87A5-468A-A861-0199147FC382

P356

Q33333673-CB4C6EA5-3462-4452-A91C-CBD2229400BE

P407

Q33333673-7B582802-E839-4015-B09A-49CAC915E1BF

P433

Q33333673-27B09F46-E191-4D6E-B45B-AE1ED0269C56

P478

Q33333673-25D04E71-B6B4-4CF3-A927-BD4888C6638B

P577

Q33333673-F0E27011-B39E-4682-B046-F25CB8CB5B22

P698

Q33333673-B6C33884-4DB2-4C76-8701-C944DA00E483

P921

Q33333673-12437165-3C6F-4CE8-9049-6A7DCF1AA3E9

P356

1097-0142(20000815)89:4%3C750::AID-CNCR5%3E3.0.CO;2-R

P1433

P1476

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

@en

P2093

C H Wang

http://www.w3.org/2001/XMLSchema#string

H M Wang

http://www.w3.org/2001/XMLSchema#string

J S Chen

http://www.w3.org/2001/XMLSchema#string

T S Yang

http://www.w3.org/2001/XMLSchema#string

Y C Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Reporting results of cancer treatment

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

Clinical trials in primary hepatocellular carcinoma: current status and future directions.

Treatment of hepatocellular carcinoma: too many options?

Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.

Optimal two-stage designs for phase II clinical trials.

P304

750-756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2000-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10951336

http://www.w3.org/2001/XMLSchema#string

P921